Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). [electronic resource]
Producer: 20120928Description: 659-65 p. digitalISSN:- 1473-5741
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Camptothecin -- administration & dosage
- Central Nervous System Neoplasms -- drug therapy
- Compassionate Use Trials
- Dacarbazine -- analogs & derivatives
- Disease Progression
- Glioma -- drug therapy
- Humans
- Irinotecan
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Retrospective Studies
- Temozolomide
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.